Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Long Hong

Showing results (161-170 of 175) with videos related to

Pageof 18
Sort By:
Cancer Medicine|February 3, 2026
Analysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122Anthony T C Chan, Victor Ho Fun Lee, Ruey-Long Hong, et al.
Cancer Immunology Research|September 23, 2018
A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell KillingPatrick H Lizotte, Ruey-Long Hong, Troy A Luster, et al.
Cancer Medicine|October 21, 2025
Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II TrialMuh-Hwa Yang, Shang-Yin Wu, I-Wei Ho, et al.
Targeted Oncology|October 24, 2023
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaAlbiruni R Abdul Razak, Hung-Ming Wang, Jang-Yang Chang, et al.
Oral Oncology|December 15, 2023
Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-PacificYe Guo, Torahiko Nakashima, Byoung Chul Cho, et al.
Oral Oncology|April 5, 2022
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048Danny Rischin, Kevin J Harrington, Richard Greil, et al.
Annals of Hematology|November 12, 2021
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experienceYu-Wen Wang, Xavier Cheng-Hong Tsai, Hsin-An Hou, et al.
Lancet (London, England)|November 5, 2019
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyBarbara Burtness, Kevin J Harrington, Richard Greil, et al.
Plant Biotechnology Journal|July 7, 2019
Identification of loci controlling adaptation in Chinese soya bean landraces via a combination of conventional and bioclimatic GWASYing-Hui Li, Delin Li, Yong-Qing Jiao, et al.
Clinical and Translational Radiation Oncology|December 22, 2021
Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patientsPierre Blanchard, Anne W M Lee, Alexandra Carmel, et al.
Pageof 18

Showing results (161-170 of 175) with videos related to

Sort By:
Pageof 18
Cancer Medicine|February 3, 2026
Analysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122Anthony T C Chan, Victor Ho Fun Lee, Ruey-Long Hong, et al.
Cancer Immunology Research|September 23, 2018
A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell KillingPatrick H Lizotte, Ruey-Long Hong, Troy A Luster, et al.
Cancer Medicine|October 21, 2025
Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II TrialMuh-Hwa Yang, Shang-Yin Wu, I-Wei Ho, et al.
Targeted Oncology|October 24, 2023
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaAlbiruni R Abdul Razak, Hung-Ming Wang, Jang-Yang Chang, et al.
Oral Oncology|December 15, 2023
Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-PacificYe Guo, Torahiko Nakashima, Byoung Chul Cho, et al.
Oral Oncology|April 5, 2022
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048Danny Rischin, Kevin J Harrington, Richard Greil, et al.
Annals of Hematology|November 12, 2021
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experienceYu-Wen Wang, Xavier Cheng-Hong Tsai, Hsin-An Hou, et al.
Lancet (London, England)|November 5, 2019
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyBarbara Burtness, Kevin J Harrington, Richard Greil, et al.
Plant Biotechnology Journal|July 7, 2019
Identification of loci controlling adaptation in Chinese soya bean landraces via a combination of conventional and bioclimatic GWASYing-Hui Li, Delin Li, Yong-Qing Jiao, et al.
Clinical and Translational Radiation Oncology|December 22, 2021
Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patientsPierre Blanchard, Anne W M Lee, Alexandra Carmel, et al.
Pageof 18